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Background: Cognitive adaptation training (CAT) targets the adaptive behaviour of patients with schizophrenia
and has shown promising results regarding the social aspects of psychosocial treatment. As yet, no reports have
appeared on the use of CAT in combination with assertive community treatment (ACT). Our purpose was to
evaluate the effect of CAT in comparison with ACT, focusing on social functions (primary outcome), symptoms,
relapse, re-hospitalisation, and quality of life of outpatients with schizophrenia.
Methods: The trial was a parallel, randomised, multicentre trial conducted in three centres treating patients with
a ﬁrst episode of schizophrenia disorder. A total of 62 outpatients diagnosed as having schizophrenia were
randomly assigned to CAT+ACT or ACT alone. The CAT was conducted in the patient's home and included
instruction in prompting for speciﬁc actions. The treatment lasted for 6 months, and the patients were assessed
at baseline and at 6- and 9-month follow-ups.
Results: The results ofmixed-effects regressionmodels indicated no signiﬁcant differences between intervention
group and control group at 6 and 9 months in any outcome [Global Assessment of Functioning at 6 months
(p=0.32) and the Health of the Nation Outcome Scales social subscale at 6 months (p=0.30)].
Conclusion: The results from this trial differ from previous CAT trials because use of CAT showed no signiﬁcant
effects. However, the low number of participants may have been responsible for these results. Thus, additional
studies are needed to determine whether the use of some elements of CAT can help to make ACTmore econom-
ically effective.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Approximately 75% to 85% of patients with schizophrenia have
cognitive impairments (Johnson-Selfridge and Zalewski, 2001; Kurtz
et al., 2005; Pfammatter et al., 2006). Impairments have a negative
inﬂuence on patients' ability to maintain work, contact with friends,
and independent living and functioning social relationships (Green
et al., 2000). Although antipsychotic treatment can decrease cognitive
impairment, it cannot eliminate these problems (Peuskens et al.,
2005). It therefore seemed relevant to develop compensatory strategies
for the remaining cognitive impairments.
Cognitive adaptive training (CAT) has shown promising effects on
patients with schizophrenia in terms of an enhanced level of social
functioning, decreased relapse rates, and higher compliance compared
to treatment as usual. CAT is designed to bypass cognitive deﬁcits by
rearranging the environment to support and sequence appropriate
behaviours (Velligan et al., 2008b).
CAT has so far only been tested in comparisonwith groups receiving
active comparator conditions and treatment as usual (i.e. standard
medication follow-up provided by a community outpatient clinic). In
the setting for the present trial, assertive community treatment (ACT)
was already the standard treatment and included a low case load for
the team members who attempted to provide all the psychiatric and
social care the patients required at home (Marshall and Lockwood, 1998).
We combined CAT with ACT to investigate whether CAT would
show the same promising effects on patients with schizophrenia in
this setting. Although CAT and ACT both use support as an essential
element in intervention, CAT and ACT interventions differ in both
ideas and methods. CAT places the primary focus on cognitive impair-
ment and the strategies to bypass these (Velligan and Bow-Thomas,
2000), where ACT focuses on helping the patient to live in the
community with a disease (McGrew et al., 1994; Burns, 2010). CAT
uses individual training on social abilities (Velligan and Bow-Thomas,
2000), where ACT uses support and contacts in the environment to
help the patient in regard to symptoms, social problems and daily living
(McGrew et al., 1994; Burns, 2010).
Schizophrenia Research 135 (2012) 105–111
⁎ Corresponding author at: Mental Health Services in the Region of Southern
Denmark — Esbjerg, Gl. Vardevej 101, 6715 Esbjerg N, Denmark. Tel.: +45 2479 3539.
E-mail address: jens.peter.hansen@psyk.regionsyddanmark.dk (J.P. Hansen).
0920-9964/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.schres.2011.12.014
Contents lists available at SciVerse ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schres
To our knowledge the trial was the ﬁrst trial on the effect of CAT in
an ACT setting. The trial was also the ﬁrst to target patients with ﬁrst-
onset of psychoses.
The aim of the trial was to evaluate the effect of CAT+ACT versus
ACT alone, with focus on social functions, symptoms, relapse,
re-hospitalisation, and quality of life of outpatients with schizophrenia.
2. Materials and methods
The trial was a randomised multicentre trial of 62 outpatients
allocated to CAT+ACT or ACT alone. The patients were included
consecutively from three outpatient clinics in Southern Denmark
specialising in the treatment of patients with schizophrenia. The
patients completed baseline assessment before randomisation into
one of two groups: CAT+ACT or ACT alone group. After randomisation,
the patients were treated for 6 months and then the patients were
followed up for an additional 3 months. The environmental supports
(e.g., signs, text message-systems) remained in use in the CAT+ACT
group after the 6-month treatment period. Assessments of symptoms
and functioning were conducted at baseline, at 6, and 9 months.
2.1. Patients
From 1 January 2009 to 31 July 2010, 66 patients with a diagnosis
in the schizophrenia spectrum (ICD codes in the F2 category) who
had been treated for more than 1 year at a psychiatric clinic treating
patients with a ﬁrst episode of schizophrenia disorder and who
received psychotherapeutic medication and psychosocial treatment
were included in the trial. Patients living at an institution, patients
who did not speak or understand Danish, and patients who did
wish to participate were excluded.
The patients were identiﬁed through contact to the centres. The
eligible patients were informed of the possibility of taking part in
the project by a member of the primary staff. The patients were
given details of the trial by the ﬁrst author in the patients' homes.
The trial was approved from the local ethics review board
(S-20080037), and all included patients signed an informed consent
and could withdraw without account.
2.2. Blinding
Group assignment was blinded only for the assessors. The assessors
were independent of the research team, were involved only in follow-
up interviews, and were kept blinded to treatment allocation. The
patients were told not to give the assessors information about their
group assignments.
2.3. Randomisation
The included patients were centrally randomised to CAT+ACT or
ACT alone. The randomisation was carried out through a centralised
telephone voice response randomisation. The allocation sequence
was computer generated, and stratiﬁed for each of the three centres
and for social functioning assessed using The Health of the Nation
Outcome Scales' (HoNOS) items 9–12 (social problems subscale).
The allocation sequence was concealed until the voice response call.
2.4. Intervention and control arm
All the patients received ACTwith regular contactwith a physician, a
community mental health nurse, and a social worker. The treatment
included medications and weekly contact with professionals (often in
patients' homes). Additionally, all patients received treatment accord-
ing to the concept described in the OPUS trial (Thorup et al., 2005)
including psychoeducation, and social skill training in groups and
psychosocial intervention with relatives.
Additionally, patients in the intervention arm received training
regarding the solving of concrete problems related to daily life using
tools such as schedules, schemes, and signs. The intervention was
conducted in the patients' homes in accordance with a revised CAT
manual every 14 days for a period of 6 months. All the interventions
were provided by the same person who was responsible for the
revisions of the CAT manual. This person had long experience in treating
patientswith schizophrenia andwas theoretically prepared in conducting
CAT by scientiﬁc immersion in cognition and training during a PhD
course. The intervention was based on assessment of neurocognitive
function using the Frontal Systems Behavior Scale (FrSBe) (Velligan and
Bow-Thomas, 2000) and the Wisconsin Card Sorting Test CV4 (WCST)
(Heaton et al., 1993). The executive functions were assessed using
WCST (contrary to a composite assessment in the original CAT treat-
ment). Patients who completed fewer than four categories or had more
than 15% perservative errors on the WCST were categorised as having
poor executive functions (Thurston-Snoha and Lewine, 2007;
Rodriguez-Jimenez et al., 2008). Patients who had increased scores on
apathy received environmental prompts (i.e. automatic short message
service (SMSs)) to initiate and complete daily activities. Patients who
had increased scores on the disinhibition subscales received help to
organise belongings and remove distracting objects from the environ-
ment so that they could focus on their daily activities. Patients with
high scores on the executive subscale received extensive support and a
stronger and clearer indication from environmental cues. Patients with
no increase in subscale score received environmental prompts and tools
to support daily activities as needed.
2.5. Assessments
At trial entry and at 6 and 9 months, the following information
was collected.
2.5.1. Primary outcome
The global social functioning was assessed using the Global
Assessment of Function (GAF-F) (Startup et al., 2002). The speciﬁc
social functioning was assessed using HoNOS social problems subscale.
The instrument assesses problems with relationships, activities of daily
living, living conditions, occupations, and activities (Wing et al., 1998).
2.5.2. Secondary outcome
Social needs were assessed using the Camberwell Assessment of
Need (CANSAS) items1–5 and11–24 (Andresen et al., 2000). Symptoms
were assessed using the Positive and Negative Syndrome Scale (PANSS)
(Kay et al., 1988). Quality of Life was assessed using Lehman Quality of
Life Interview, Brief Version (L-QoLI) (Melle et al., 2005).
Data on hospitalisation recorded as the number of hospitalisations,
the number of bed-days, and the reasons for hospitalisation were
collected from the hospital records.
2.6. Inter-rater reliability
Two investigators trained in the outcome assessments did the
assessments. After more than 15 completed interviews, the investiga-
tors were assessed for reliability. The reliability test was conducted on
the basis of eight PANSS interviews inwhich investigators did individual
ratings. We calculated the intraclass correlation coefﬁcient (ICC) for
each item to control test–retest reliability. The ICC was considered
positive for group comparison (ICC=0.89).
2.7. Statistical methods
Differences in functional outcome over time by intervention group
and controls were assessed using multilevel mixed-effects linear
regression analysis with unstructured variance matrix where the
baseline values of the outcomes were used as covariates. p values
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above 0.05 were considered signiﬁcant. Skewed variables were power
transformed if possible; otherwise the variables were transformed
into dichotomous responses. Missing values were replaced using
multiple imputation (m=20) (Schafer and Graham, 2002). This
approach assumes that the distribution of missing data could be
estimated from the information from previous interviews under the
assumption that data were missing at random. The model was
checked using residual plots and the Shapiro–Wilk test. For time to
readmission, weused a stratiﬁedCox regression to relax the assumptions
of proportional hazards. Survival times were plotted in a Kaplan–Meier
survival curve. All analyses in the 62 patients were done on the principle
of intention to treat. The analyses were conducted in the statistical soft-
ware programme Stata 11.
2.8. Power calculation
When the trial was planned, we considered social functioning to
be the primary outcome. We expected a mean reduction in HoNOS
social subscale from 8 to 6 points, with a standard deviation of 3.5
in both groups. With a 0.05 level of signiﬁcance and 90% power, 65
patients were required for each study group. Thus, we planned an
inclusion of 164 patients, with compensation for 20% attrition during
follow-up. However, only 62 patients were randomised because of
exclusions and refusals. The reduced group size gave us the ability
to detect a difference of 3 points between groups on the HoNOS social
subscale.
3. Results
3.1. Baseline characteristics
The ﬂow chart for the trial is presented in Fig. 1. Of the 366 eligible
patients, 300 were excluded: 59 patients did not fulﬁl the inclusion
criteria, 29 met the exclusion criteria (20 living at institutions, 6 did
not understand Danish, and 3 lived with someone included in the
study), 191 refused to participate, and 21 could not participate (19
Assessed for eligibility
(n = 366)
Randomised (n = 62)
Excluded (n = 300)
Under 1 year at centre (n =6)
No schizophrenia diagnose (n =33)
No psychiatric treatment (n =20)
Living at an institutions (n =20)
Does not understand Danish (n =6)
Living with included (n =3)
Other reasons ( n=21)
Refused to participate (n =191) 
Baseline assessment (n = 66)
Allocated to intervention (n = 31)
Did not receive allocated intervention due to 
hospitalization (n =3)
Allocated to control  (n = 31)
Lost to follow-up (n=6) 
Withdrawn consent (n= 6)
Lost to follow-up (n=5) 
Withdrawn consent (n= 4)
Not available (n =1)
Dropout before randomisation
(n = 4)
Outcome assessment at
six month (n = 25) 
Outcome assessment at 
six month (n = 26)
Outcome assessment at nine 
month (n = 24)
Outcome assessment at nine 
month (n = 21)
Lost to follow-up (n=7) 
Withdrawn consent (n= 6)
Not available (n =1)
Lost to follow-up (n=10) 
Withdrawn consent (n= 4)
Not available (n = 6)
Fig. 1. Flow chart.
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moved or were discharged from treatment centres and 3were evaluated
to be too psychotic to undergo baseline assessments). Before randomisa-
tion 4 patients dropped out, leaving 62 patients for randomisation and
analysis. After randomisation, 6 patients in the CAT+ACT group and 4
patients in the ACT alone grouped withdrew consent. Additionally, at
the 6-month follow-up, 1 patient in the ACT alone group and 1 patient
in the intervention group could not be located, and at the 9-month
follow-up, 6 patients in ACT alone group could not be located.
Table 1 summarises the demographic and some of the baseline
variables by treatment group. The clinical characteristics were similar
except for the percentages of perservative errors and differences
between centres. Patients in the intervention group had a higher
percentage of perservative errors [14% (SD=7)] compared to the
patients in the intervention group [10% (SD=10)]. The patients from
one centre had a higher mean age [25.4 years (SD=11.1)] than in the
two other centres [22.1 years (SD=1.7) and 26.6 years (SD=4.8)].
The times from onset of schizophrenia to randomisation were likewise
longer at this centre [8.3 years (SD=7.8)] than at the other two centres
[2.0 years (SD=0.22) and 1.9 years (SD=0.86)]. The HoNOS social
subscale scores were higher at this centre [6.3 (SD=3.5)] than at the
two other centres [4.8 (SD=4.3) and 4.0 (SD=3.5)].
3.2. Primary outcomes
The results indicated no signiﬁcant differences in primary outcome
GAF at 6 months (p=0.32) or 9 months (p=0.34) and no signiﬁcant
differences in HoNOS social subscale at 6 months (p=0.30) and
9 months (p=0.15). The non-signiﬁcant mean improvement in GAF
was 1.5 in favour of the intervention group, as illustrated in Fig. 2.
Analyses of effect of time showed no signiﬁcant improvements on
GAF at 9 months for the CAT+ACT group (p=0.42) or the ACT
alone group (p=0.36). The time effect on HoNOS was signiﬁcant at
9 months for the ACT+CAT group (p=0.004) and for the ACT alone
group (p=0.05).
3.3. Secondary outcome and control for confounders
The secondary outcomewas not signiﬁcantly different in the CAT+
ACT group compared to the ACT alone group at any time for any
outcome, as illustrated in Table 2. However, analyses of effect of time
indicated a consistent improvement on some secondary outcomes, as
illustrated in Table 3 and Fig. 2. After a Bonferonni correction (Altman,
1999) the analysis showed signiﬁcant results at 9 months on CANSAS
in the ACT alone group (p=0.03). The PANSS was signiﬁcantly
improved over time (p=0.05) in the ACT alone group, and improve-
ments over time were seen in L-QoLi in the CAT+ACT group (p=0.02)
and the ACT alone group (p=0.01). The time from randomisation to
relapse did not differ signiﬁcantly between the groups according to
analysis with the proportional hazards regression model (p=0.75). The
times to readmission illustrated in the survival curves for the treatment
group over time are presented in Fig. 3. There were no signiﬁcant differ-
ences in the time patients spent in hospital (p=0.79).
The analysis showed no effect of confounders on neither primary
nor secondary outcomes. The list of confounders included age, sex,
education, substance abuse, centre, occupational background, anti-
psychotic medication (sort), diagnosis, years in centre, days at hospital
in intervention period, contacts to psychiatrist, contacts to emergency
ward, contacts to primary teammember (PTM), and caseload for primary
team member.
The patients included in this trial had similar social functioning
(GAF=40) compared to the patients who refused to participate
(GAF-F=38).
3.4. Fidelity
The ﬁdelity of the delivered ACT was assessed according to
McGrew et al. (1994) showing high ﬁdelity on all items except a
mean caseload at 13.8 (SD=4.5) which is 3.8 over recommended
caseload. A staff member's caseload in the community mental health
centres varied between 1:5 patients and 1:22 patients. The patients
received 0.61 (SD=0.26) visits a week, on average. The CAT treat-
ment was delivered according to the CAT manual to all but three
patients admitted to hospital part of the time for the intervention. The
mean number of interventions was 8.1 (SD=4.3). The interventions
were applied to all areas described in the CAT manual with highest
frequency regarding social skills (60%), work skills (33%) and medica-
tion management (27%). The tools used in the intervention included
all the tools described in the manual with highest frequency regarding
messages on mobile phones (37%) and use of schedules (37%).
4. Discussion
In this trial comparing CAT+ACT versus ACT alone, we investigated
whether patients receivingCATmight beneﬁt with regard to social func-
tioning, symptoms, admission to hospitals, and quality of life. To thebest
of our knowledge this is the ﬁrst trial in an ACT setting. However, there
are some limitations that have to be taken into consideration. (1) There
were no assessments of conceivable contamination with CAT interven-
tions in the ACT alone group. The contaminationswere solely prevented
by admitting the CAT intervention to the patients from a person outside
the ACT team (the ﬁrst author). (2) The CAT treatments were admitted
by a staff without practical training in CAT andwithout supervision from
experienced CAT providers. (3)The low number of patients in the study
may have resulted in accepting a false null hypothesis, giving a type II
error. We planned to avoid this problem by calculating power to
demonstrate signiﬁcant results. However, the estimated number of
patients was not reached because 300 had to be excluded; mostly
patients who did not want to participate. Attention to refusers is crucial
in trials involving patients with schizophrenia because many of these
patients have difﬁculty making decisions (Candilis et al., 2008) and
lack interest in research projects (Candilis et al., 2006). Thus, we includ-
ed all centres in the region to get access to enough patients. However,
the large number of patients refusing to participate made it impossible
to conduct this project as originally planned. The high refusal rate
might come from a practice where the patients were initially informed
through the patient's primary mental health worker. Most of the
refusers did not want to meet the primary researcher. Thus, lack of
sufﬁcient support inmaking the decision tomeet the primary researcher
may have induced some refusals.
Table 1
Demographic and clinical characteristics.
Intervention
(N=31)
Control
(N=31)
Variable
Gender, male 19 (61) 21 (68)
Age (years), mean (SD) 33.2 (11.4) 32.8 (10.3)
Clinical characteristics
Diagnosis
F20.0 paranoid schizophrenia 22 (71) 27 (87)
F20.3 undifferentiated schizophrenia 4 (13) 0 (0)
F20.6 simple schizophrenia 1 (3.2) 0 (0)
F20.9 schizophrenia, unspeciﬁed 4 (13) 4 (13)
Years since onset of schizophrenia,
mean (SD)
6.4 (6.6) 7.1 (8.0)
Diagnosed abuse 5 (16) 7 (23)
WCST, categories completed, mean (SD) 4.8 (1.9) 5.1 (1.9)
WCST perservative errors in percent,
mean (SD)
10 (5) 14 (7)
Values are numbers (percentages) unless stated otherwise. WCST = Wisconsin Card
Sorting Test.
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Despite the lack of power, the results showed a non-signiﬁcant,
inﬁnitesimally small mean difference of 0.5 on the HoNOS social sub-
scale in favour of CAT treatment. When we did a power calculation
from the results, it gave an estimated population of 2.328 patients
at 90% power to demonstrate signiﬁcance. However, an improvement
of 0.5 on the HoNOS social subscale would not be clinically relevant.
Fig. 2. GAF, PANSS and L-Qoli (for CAT and control groups).
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Previous results from studies of CAT have shown signiﬁcant
improvements in the CAT groups in comparison with the control
groups (Velligan et al., 2008b, 2009). One trial has shown effect of
CAT and Generic Environmental Supports (GES) on social functioning
compared to treatment as usual (Velligan et al., 2008a). However, the
differences in social functioning between the CAT group and the GES
group were only reported signiﬁcant on the Social and Occupational
Functioning Scale (SOFAS) (pb0.03) andnot on the adaptiveMultnomah
CommunityAbility Scale (MCAS) (Velligan et al., 2008a). GES is amanual-
driven series of environmental supports provided monthly by telephone
calls regarding the use of checklist of everyday activities, pill containers,
and reminder signs (Velligan et al., 2006). In the present trial, treatment
as usual was more intensive than that in the GES group in regard to
time spent with patients, in instructions in correct medication manage-
ment, and adjusting the medication. Thus, the lack of signiﬁcant results
on primary outcome in the present trial is in accordance with previous
results showing no signiﬁcant differences between GES and CAT on
MCAS. Additionally, the general social functioning in previous trial was
assessed using the SOFAS instrument contrary to GAF in the present
trial. The SOFAS instrument might be more sensitive to changes in
adaptive functioning in regard to the treatment (Hilsenroth et al.,
2000). Consequently, an assessment using adaptive instruments such as
MCAS and more sensitive instruments like SOFAS might have generated
signiﬁcant differences between groups in this trial. In regard to previous
OPUS studies, the improvement in mean GAF over time was smaller
than in previous OPUS studies (Petersen et al., 2005).
There was no signiﬁcant change in symptoms between groups as
in previous CAT studies. However, the positive symptoms on PANSS
changed signiﬁcantly over time in contrast to previous studies of
CAT. The changes of positive symptoms over time were similar to
the improvements in the intervention group in the OPUS study
(Petersen et al., 2005).
The time to readmission to hospital was not signiﬁcantly different
between groups in this trial in contrast to previous CAT studies
(Velligan et al., 2008b). However, the time to readmission was longer
in this trial for both groups than the time to readmission in the
intervention group in previous CAT studies.
Drop-out analysis showed signiﬁcantly more drop-outs among
women than men (p=0.013). More men than women were
diagnosed as substance abusers. Thus, substance abuse and gender
were included in all analyses of outcome. However, neither gender
nor substance abuse had any effect on outcome.
CAT+ACT did not improve social functioning and Quality of Life
or reduce symptoms and readmission signiﬁcantly compared to ACT
alone treatment in this ﬁrst trial of CAT added to ACT treatment.
Therefore, we still do not know the most efﬁcient compensatory
treatment in regard to cognitive impairment in an ACT setting.
Further studies on the effectiveness of combinations of ACT and CAT
are needed to determine whether use of elements from CAT can
improve functional outcomes in schizophrenia.
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Table 2
Clinical outcomes of patients who received CAT treatment or standard treatment.
CAT treatment Control group p value at
6 months
p value at
9 months
Baseline 6 months 9 months Baseline 6 months 9 months
GAF, function 40.9 (9.5) 43.1 (11.2) 43.3 (11.6) 38.4 (8.7) 38.5 (10.2) 41.3 (9.4) 0.808 0.989
HoNOS 5.8 (3.5) 5.1 (3.4) 4.6 (3.5) 5.7 (3.7) 5.3 (3.8) 3.9 (2.6) 0.783 0.873
CANSASa 2.7 (2.6) 1.8 (2.4) 1.6 (2.5) 3.3 (2.6) 2.1 (2.5) 1.3 (1.6) 0.842 0.951a
PANSS positive 19.5 (5.6) 16.7 (5.9) 16.4 (5.7) 20.6 (6.6) 17.7 (6.7) 16.3 (4.9) 0.918 0.753
PANSS negative 21.9 (7.2) 20.4 (6.4) 21.0 (6.3) 22.5 (8.7) 21.0 (8.4) 20.8 (7.3) 0.951 0.870
PANSS general 41.9 (10.3) 37.6 (11.6) 37.8 (9.9) 43.3 (13.0) 39.8 (14.1) 34.6 (10.2) 0.903 0.399
L-QoLI life in general 4.26 (1.2) 4.76 (1.4) 5.0 (1.2) 4.6 (1.1) 4.8 (1.6) 5.2 (0.94) 0.673 0.976
Values are mean (SD) unless stated otherwise.
GAF = Global Assessment of Functioning, functioning scale.
HoNOS = Health of the Nation of Outcome Scales, social problems subscale.
PANSS = Positive and Negative Syndrome Scale, the positive, negative, and general subscales.
L-QoLI = Lehman Quality of Life Interview — brief version, item 1: life in general.
CANSAS = Camberwell Assessment of Need on unmet needs at items 1–5 and 11–24.
a The p-values for CANSAS were analysed after transformation to dichotomous response, 0 = no unmet needs and 1 = one or more unmet needs.
Table 3
Signiﬁcant changes over time for both groups.
6-months p-value
of interaction
9-months p-value
of interaction
CANSAS
Control group 0.027 0.004
Intervention group 0.039 0.018
PANSS positive
Control group 0.019 0.007
Intervention group 0.026 0.013
L-QoLI life in general
Control group 0.010 0.002
Intervention group 0.020 0.003
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